Ajanta Pharma Limited has submitted its voluntary Sustainability Report for FY26, prepared with reference to GRI Standards. The disclosure highlights a 47% reduction in Scope 1 emissions and the achievement of zero workplace fatalities across its operations during the fiscal year.

The report, filed under Regulation 30 of SEBI (LODR) Regulations, 2015, complements the mandatory Business Responsibility and Sustainability Report (BRSR). It details the company's environmental, social, and governance initiatives, including a significant expansion in renewable energy capacity to 16.6 MW, which now meets 34% of total energy needs.

Environmental Performance and Decarbonisation

The company achieved a substantial decrease in direct greenhouse gas emissions, reducing Scope 1 emissions from 6,392 tCO2e in the prior year to 3,364 tCO2e in FY26. This reduction was driven by the commissioning of additional solar power installations and the replacement of fossil fuels with biomass-fired boiler systems at key facilities.

Combined Scope 1 and Scope 2 emissions remained flat at approximately 49,940 tCO2e despite revenue growth, indicating improved operational efficiency. Water stewardship efforts included Zero Liquid Discharge practices across manufacturing facilities and rural conservation projects creating 1.5 lakh KL of annual potential.

Social Impact and Workplace Safety

Ajanta Pharma reported zero fatalities, high-consequence injuries, or lost-time injuries across 10,404 employees and 2,802 workers. Six major sites are certified for ISO 14001 and ISO 45001 standards. The company maintained its Great Place To Work certification for the fourth consecutive year and was named a Most Preferred Workplace for Women.

Community engagement saw a CSR spend of ₹23.73 crore, exceeding the statutory obligation by 18.1%. This funding reached 3.63 lakh people through health, education, and sports initiatives. Additionally, 28% of input material was sourced from MSMEs and small producers, up from 15% in the previous year.

Governance and Operational Highlights

Governance structures were strengthened with formal AI-risk identification across R&D, manufacturing, and supply chain functions. The Board comprises 25% women directors, and 100% of senior management is covered under the Code of Conduct. No whistle-blower complaints, bribery incidents, or data breaches were recorded during the year.

What the Numbers Show

The juxtaposition of flat combined Scope 1 and 2 emissions against reported revenue growth suggests that Ajanta Pharma’s decarbonisation efforts are effectively offsetting the carbon intensity typically associated with increased production volumes. The shift from incineration to co-processing for hazardous waste, where landfill disposal dropped to 0.7 MT, further indicates a strategic pivot toward circular economy principles rather than mere compliance.

Ajanta Pharma Limited promoter Aayush Agrawal, acting as trustee of the Aayush Agrawal Trust, has released a pledge on 98,185 equity shares of the company. The release, reported to stock exchanges on September 28, 2026, was executed to facilitate loan repayment obligations.

The disclosure was made under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The transaction involved the gradual release of pledged shares held with Aditya Birla Capital Ltd across three dates in late September 2026.

Breakdown of pledge release events

The promoter’s holding in Ajanta Pharma stands at 1,41,12,924 shares, representing 11.29% of the total share capital. Prior to these releases, 1,17,40,571 shares (9.40%) were already encumbered. The recent activity reduced this encumbered portion through three distinct tranches.

The total number of shares released amounts to 98,185. Consequently, the post-event holding of encumbered shares for Aayush M Agrawal (Trustee) is now 1,16,42,386 shares, which constitutes 9.32% of the company's total share capital.

Other promoter holdings

The filing also detailed the status of other promoters and persons acting in concert (PAC). While several entities hold significant stakes, no new encumbrances or releases were reported for them during this specific disclosure period.

• Gabs Investments Pvt Ltd: Holds 1,25,88,393 shares (10.07%), with 27,70,000 shares (2.22%) currently encumbered.
• Yogesh M Agrawal (Trustee): Holds 1,80,78,147 shares (14.47%), with no shares encumbered.
• Rajesh M Agrawal (Trustee): Holds 1,80,78,148 shares (14.47%), with no shares encumbered.
• Ravi P Agrawal (Trustee): Holds 1,27,92,904 shares (10.24%), with 14,73,390 shares (1.18%) currently encumbered.
• Ganga Exports: Holds 33,48,261 shares (2.68%), with no shares encumbered.

What the numbers show

The reduction in Aayush Agrawal’s pledged shareholding from 9.40% to 9.32% indicates a marginal deleveraging of his personal stake. Despite this release, a substantial portion of his holding remains encumbered, accounting for approximately 82.5% of his total personal shareholding in the company. This high ratio of pledged-to-held shares suggests that while debt is being serviced, the promoter maintains a significant leverage position relative to his equity stake.